Xylan from Pineapple Stem Waste: a Potential Biopolymer for Colonic Targeting of Anti-inflammatory Agent Mesalamine
We have successfully conjugated mesalamine (5-aminosalicylic acid, 5-ASA) with xylan, a biopolymer isolated from pineapple stem waste, to form xylan-5-ASA conjugate. The biopolymer was used to provide colon-targeting properties for 5-ASA, a golden standard anti-inflammatory agent commonly used for ulcerative colitis treatment. A series of data from FTIR spectroscopy, UV-Vis spectrophotometry, and HPLC confirmed the xylan-5-ASA conjugate formation. To ensure successful colon targeting properties, in vitro and in vivo drug release studies after oral administration of xylan-5-ASA conjugate to Wistar rats were performed. Xylan-5-ASA conjugate was able to retain 5-ASA release in the upper gastrointestinal tract fluid simulation but rapidly released 5-ASA in the rat colon fluid simulation. In vivo release profile shows a very low peak plasma concentration, reached at 6 h after xylan-5-ASA conjugate administration. The delayed release and the lower bioavailability of 5-ASA from xylan-5-ASA conjugate administration compared to free 5-ASA administration confirmed the successful local colon delivery of 5-ASA using xylan-5-ASA conjugate. The administration of xylan-5-ASA conjugate also exhibited greater efficacy in recovering 2,4,6-trinitrobenzene sulfonic acid-induced colon ulcer compared to free 5-ASA administration. Taken together, xylan isolated from pineapple stem waste is promising to obtain colon targeting property for 5-ASA.
KEY WORDSxylan 5-ASA colon targeting colonic drug delivery ulcerative colitis
The project was financially supported by Bandung Institute of Technology (ITB) through “Innovative Research Grant” scheme year 2017.
Compliance with Ethical Standards
All institutional and national guidelines for the care and use of laboratory animals were followed. School of Pharmacy, Bandung Institute of Technology, Indonesia. The approval number is 305/UN6.C.10/PN/2017 (15/3/2017).
Conflict of Interest
The authors declare that they have no conflict of interest.
- 2.da Silva AE, Marcelino HR, Gomes MCS, Oliveira EE, Nagashima T Jr, Egito EST. Xylan, a promising hemicellulose for pharmaceutical use. In: Verbeek CJR, editor. Products and applications of biopolymers. Rijeka: InTech; 2012. p. 62–5.Google Scholar
- 8.Kong W, Gao C, Hu S, Ren J, Zhao L, Sun R. Xylan-modified-based hydrogels with temperature/pH dual sensitivity and controllable drug delivery behavior. Materials. 2017;10(304):1–3 9–10.Google Scholar
- 16.Katz S, Lichtenstein GR, Safdi MA. 5-ASA dose-response, maximizing efficacy and adherence. Gastroenterol Hepatol. 2010;6(2):1–16.Google Scholar
- 18.Gamboa JM, Leong KW. In vitro and in vivo models for the study of oral delivery of nanoparticles. Adv Drug Deliv Rev. 2013;65:800–10 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3773489/pdf/nihms453288.pdf.PubMedPubMedCentralCrossRefGoogle Scholar
- 19.(724) Drug release. USP 38–NF 33. 38th ed. Rockville, MD: United States Pharmacopeial Convention; 2015. p. 497–504.Google Scholar
- 20.Dangi AA, Ganure AL, Divya J. Formulation and evaluation of colon targeted drug delivery system of levetiracetam using pectin as polymeric carrier. J Appl Pharm Sci. 2013;3:78–87.Google Scholar
- 22.Rachmawati H, Pradana AT, Safitri D, Adnyana IK. Multiple functions of D-α-tocopherol polyethylene glycol 1000 succinate (TPGS) as curcumin nanoparticle stabilizer: in vivo kinetic profile and anti-ulcerative colitis analysis in animal model. Pharmaceutics. 2017;9(3):1–13.Google Scholar
- 25.Kumar S, Negi YS. Corn cob xylan-based nanoparticles: ester prodrug of 5-aminosalicylic acid for possible targeted delivery of drug. J Pharm Sci Res. 2012;4(12):1995–2003.Google Scholar
- 29.Rajesh A, Bharat C, Sangeeta A. Oral colon targeted drug delivery system: a review on current and novel perspectives. J Pharm Innov. 2012;1(5):6–12.Google Scholar
- 38.Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2. https://doi.org/10.1038/sigtrans.2017.23.